TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Novo Nordisk ( (NVO) ) has issued an announcement.
On November 13, 2025, Novo Nordisk announced that Mikael Dolsten, previously the Head of R&D at Pfizer, will not seek election to its Board of Directors due to personal circumstances. The Novo Nordisk Foundation and Novo Holdings A/S have decided not to propose a replacement candidate for Dolsten at the extraordinary general meeting on November 14, 2025. Instead, they plan for the Board to identify and nominate additional candidates at the Annual General Meeting in March 2026. This decision reflects the company’s strategic approach to board composition and its impact on future governance.
The most recent analyst rating on (NVO) stock is a Buy with a $62.00 price target. To see the full list of analyst forecasts on Novo Nordisk stock, see the NVO Stock Forecast page.
Spark’s Take on NVO Stock
According to Spark, TipRanks’ AI Analyst, NVO is a Outperform.
Novo Nordisk’s strong financial performance and reasonable valuation are key strengths, supporting a solid overall score. However, bearish technical indicators and challenges highlighted in the earnings call, such as market share loss and restructuring, weigh on the score. The company’s strategic focus on long-term growth and attractive dividend yield provide additional support.
To see Spark’s full report on NVO stock, click here.
More about Novo Nordisk
Novo Nordisk is a leading global healthcare company founded in 1923 and headquartered in Denmark. The company focuses on defeating serious chronic diseases, particularly through its heritage in diabetes care. Novo Nordisk is known for pioneering scientific breakthroughs, expanding access to medicines, and working towards disease prevention and cure. It employs approximately 78,500 people across 80 countries and markets its products in around 170 countries. Novo Nordisk’s B shares are listed on Nasdaq Copenhagen and its ADRs on the New York Stock Exchange.
Average Trading Volume: 15,565,438
Technical Sentiment Signal: Sell
Current Market Cap: $222B
See more insights into NVO stock on TipRanks’ Stock Analysis page.